Lista de obras -

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

artículo científico publicado en 2017

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells

artículo científico publicado en 2017

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

article

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

artículo científico publicado en 2019

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

artículo científico publicado en 2017

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

artículo científico publicado en 2016

A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy

artículo científico publicado en 2012

Absence of Grail promotes CD8+ T cell anti-tumour activity

artículo científico

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma

artículo científico publicado en 2014

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook

artículo científico publicado en 2012

Advances in the development of cancer immunotherapies

artículo científico

Advances in the treatment of metastatic melanoma: adoptive T-cell therapy

artículo científico publicado en 2012

Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals ⬇️

artículo científico publicado el 12 de febrero de 2011

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

artículo científico publicado en 2020

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

artículo científico publicado en 2015

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

artículo científico publicado en 2015

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

scientific article published on 21 May 2020

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

artículo científico publicado en 2020

Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.

artículo científico publicado en 2012

Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target

artículo científico publicado en 2020

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

article

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial

article

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

scientific article published on 11 January 2019

Comprehensive T cell repertoire characterization of non-small cell lung cancer

artículo científico publicado en 2020

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function ⬇️

artículo científico publicado el 1 de abril de 2011

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity

artículo científico publicado en 2013

EXTH-30. IN SITU AUTOVACCINATION MEDIATED BY ONCOLYTIC ADENOVIRUS DELTA-24-RGDOX INDUCES EFFICACIOUS IMMUNITY AGAINST METASTATIC MELANOMA

artículo científico publicado en 2018

Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

artículo científico publicado en 2018

Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies

artículo científico publicado en 2021

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

artículo científico publicado en 2017

Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors

artículo científico publicado en 2019

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy

artículo científico publicado en 2013

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

artículo científico publicado en 2017

Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells

artículo científico publicado en 2020

Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2.

artículo científico publicado en 2003

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy

artículo científico publicado en 2013

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

artículo científico publicado en 2016

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

artículo científico publicado en 2018

Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases

artículo científico publicado en 2017

Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans.

artículo científico publicado en 2003

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

artículo científico publicado en 2015

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

artículo científico publicado en 2016

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

artículo científico publicado en 2015

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

artículo científico publicado en 2017

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control

artículo científico publicado en 2015

Molecular and immune heterogeneity in synchronous melanoma metastases.

artículo científico publicado en 2015

Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter

artículo científico publicado en 2017

Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer

artículo científico publicado en 2020

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

artículo científico publicado en 2021

Network for biomarker immunoprofiling for cancer immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

artículo científico publicado en 2021

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort

artículo científico publicado en 2020

Novel Treatments in Development for Melanoma.

artículo científico publicado en 2016

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

artículo científico publicado en 2016

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

artículo científico publicado en 2012

PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint

artículo científico publicado en 2012

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

artículo científico publicado en 2017

Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively

artículo científico publicado en 2020

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

artículo científico publicado en 2020

Phase 2 study of pembrolizumab in patients with advanced rare cancers

scientific article published on 01 March 2020

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

artículo científico publicado en 2015

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy

artículo científico publicado en 2019

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer.

artículo científico publicado en 2015

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy

artículo científico publicado en 2014

Prognostic and biologic significance of high LCK expression in ovarian cancer

artículo científico publicado en 2015

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

RNA editing derived epitopes function as cancer antigens to elicit immune responses

scientific article published in Nature Communications

Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy

artículo científico publicado en 2021

Resident Breast T Cells: The Troops Are Already There

article

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

artículo científico publicado en 2018

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

artículo científico publicado en 2017

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

artículo científico publicado en 2016

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

artículo científico publicado en 2017

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients.

artículo científico publicado en 2015

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

artículo científico publicado en 2020

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

artículo científico publicado en 2012

T cell homing therapy for reducing regulatory T cells and preserving effector T cell function in large solid tumors

artículo científico publicado en 2018

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

artículo científico publicado en 2017

TIL therapy and anti-CTLA4: can they co-exist?

Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma

artículo científico publicado en 2018

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

artículo científico publicado en 2019

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.

artículo científico publicado en 2017

The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression.

artículo científico publicado en 2018

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity

artículo científico publicado en 2015

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells

artículo científico publicado en 2013

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

artículo científico publicado en 2018

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues

artículo científico publicado en 2017

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes

artículo científico publicado en 2015

Lista de obras de

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy

Absence of Grail promotes CD8+ T cell anti-tumour activity

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook

Advances in the development of cancer immunotherapies

Advances in the treatment of metastatic melanoma: adoptive T-cell therapy

Altered decamer and nonamer from an HLA-A0201-restricted epitope of Survivin differentially stimulate T-cell responses in different individuals ⬇️

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.

Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial

Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function ⬇️

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity

EXTH-30. IN SITU AUTOVACCINATION MEDIATED BY ONCOLYTIC ADENOVIRUS DELTA-24-RGDOX INDUCES EFFICACIOUS IMMUNITY AGAINST METASTATIC MELANOMA

Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors

Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells

Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2.

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy

Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases

Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans.

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control

Molecular and immune heterogeneity in synchronous melanoma metastases.

Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter

Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Network for biomarker immunoprofiling for cancer immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort

Novel Treatments in Development for Melanoma.

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "Exercising" an alternative viewpoint

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively

Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer.

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy

Prognostic and biologic significance of high LCK expression in ovarian cancer

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

RNA editing derived epitopes function as cancer antigens to elicit immune responses

Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy

Resident Breast T Cells: The Troops Are Already There

Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells.

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients.

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients